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ABSTRACT
Background. Aromatase inhibitors (AIs) are more effec-
tive than tamoxifen as neoadjuvant endocrine therapy
(NET) for hormone receptor (HR)-positive breast cancer.
Here we report the surgical and long-term outcome of
elderly postmenopausal patients with locally advanced,
HR-positive breast cancer treated with preoperative AIs.
Methods. Between January 2003 and December 2012, 144
postmenopausal patients inoperable with breast conserva-
tive surgery (BCS) received letrozole, anastrozole, or
exemestane as NET. Patients underwent breast surgery and
received adjuvant AIs. Adjuvant systemic therapy, che-
motherapy and/or trastuzumab, and adjuvant radiotherapy
were administered as appropriate, but limited to high-risk
patients with few or no comorbidities.
Results. After a median follow-up of 49 months, 4
(3.0 %) patients had local relapse, 18 (12.5 %) had distant
metastases, and 24 (17.0 %) died. BCS was performed in
121 (84.0 %) patients. A tumor size \3 cm and human
epidermal growth factor receptor 2 (HER2) negativity were
predictors of BCS. The achievement of BCS and grade G1
were significantly associated with longer disease-free
survival (DFS) (p = 0.009 and p = 0.01, respectively) and
overall survival (p = 0.002 and p = 0.005, respectively).
Residual tumor B2 cm (yT0–yT1) in the longest diameter
after NET was also statistically associated with longer DFS
(p = 0.005).
Conclusions. The results of this retrospective study indi-
cate that elderly breast cancer patients with a tumor size
\3 cm at diagnosis and HER2 negativity have a higher
probability of achieving BCS after NET. Moreover,
patients treated with BCS and with grade G1 tumor have a
reduced risk of recurrence and death in the long-term fol-
low-up.
Neoadjuvant endocrine therapy (NET) has been histor-
ically administered to patients with locally advanced breast
cancer and unfit for chemotherapy because of age and/or
comorbidities.1,2 New perspectives on the use of NET in
healthy postmenopausal women have recently emerged on
the basis of studies showing that patients with hormone
receptor (HR)-positive breast cancer hardly achieve path-
ologic complete response (pCR) after neoadjuvant
chemotherapy, thus suggesting that HR-positive tumors are
quite resistant to this therapeutic approach.3–10 Moreover,
patients who do not achieve a pCR to neoadjuvant che-
motherapy maintain a good prognosis even in the presence
of residual disease.11,12 The good outcome of these patients
is largely dependent on the efficacy of postoperative
endocrine therapy, especially when based on the third-
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generation aromatase inhibitors (AIs) letrozole, anastroz-
ole, and exemestane. In postmenopausal women, adjuvant
AIs have been shown to be superior to tamoxifen in terms
of disease-free survival (DFS) and overall survival
(OS).13–15 Similarly, in the neoadjuvant treatment of
postmenopausal women with breast cancer, AIs allow
higher rates of objective responses and breast conservative
surgery (BCS) to be achieved than tamoxifen.16–19
Few studies have assessed the impact of response to
neoadjuvant AI on the OS of patients with HR-positive
breast cancer. This study was conducted to evaluate the
long-term outcome of elderly postmenopausal women with
locally advanced HR-positive breast cancer treated with
neoadjuvant AIs in our institution.
PATIENTS AND METHODS
Patients
The study population was identified by a systematic
review of the chart of all women with locally advanced
breast cancer, candidates to mastectomy, and consecutively
treated with NET—letrozole, anastrozole, or exemestane—
between January 2003 and December 2012. All patients
had a diagnosis of HR-positive invasive breast cancer as
established by tru-cut biopsy of the primary tumor and
immunohistochemistry (IHC), and were postmenopausal.
The study has been approved by our institutional Ethics
Committee.
Treatments
Mastectomy or BCS were performed after NET as
indicated by the surgeon. Axillary lymph node dissection
or sentinel node biopsy were performed according to sur-
geon judgment. After surgery, AIs were continued as
adjuvant treatment in all patients. Adjuvant chemotherapy
was administered to high-risk, non-responsive patients with
few or no comorbidities. Adjuvant trastuzumab was also
considered for patients with human epidermal growth
factor receptor 2 (HER2)-positive tumor. Adjuvant breast
radiotherapy was delivered to patients who underwent BCS
and to patients treated with mastectomy and stage cT3, cN2
or cN3 at diagnosis or stage pN2 after surgery. However, in
patients unfit for age or comorbidities, radiotherapy was
not administered.20
Clinical Evaluation
The clinical response to NET was evaluated by measuring
the largest diameter of the tumor by caliper at baseline, every
month and just before surgery. Mammography and breast
ultrasound were also performed, but data were not available
for all patients. The Response Evaluation Criteria in Solid
Tumors (RECIST) were utilized to define clinical responses:
complete response (CR), partial response (PR), stable dis-
ease (SD), and progressive disease (PD).21
Pathological Assessment
Tru-cut biopsies and surgical specimens were both
processed to determine morphological and molecular fea-
tures. Histological type and grade of carcinoma were
assessed on hematoxylin and eosin-stained tumor sections.
The tumor grade was scored according to the Elston–Ellis
classification. The expression of estrogen (ER), progester-
one receptors (PR), HER2, and Ki-67 were evaluated by
IHC. Cut-off positivity for HR was fixed at 10 % of tumor
cells stained for ER and/or PR.22 HER2 status was assessed
by HercepTest (Dako Italia, Milan, Italy). Tumors with a
score of 3? by IHC, or gene amplification by fluorescence
or chromogenic in situ hybridization (FISH or CISH), were
considered as HER2 positive. IHC detection of Ki-67 was
performed using the MIB-1 antibody.
pCR was defined as the absence of invasive cancer
within the breast (ypT0/is) and lymph node (ypN0), after
extensive sampling, i.e. at least ten sections, 2–4 lm in
thickness, from three different regions of the initial tumor
site, as proposed by Kuerer et al.12 Pathological stages
were categorized according to the American Joint Com-
mittee on Cancer Staging Manual, 7th edition.
Statistical Analysis
Logistic regression was applied to identify variables
predictive of BCS. The results of the model were expressed
as odds ratio (OR) and relative 95 % confidence interval
(CI). Multivariate logistic regression was applied to eval-
uate the adjusted ORs. The Kaplan–Meier method was
used to calculate the 5-year rates of DFS and OS. OS was
defined as the time between surgery and death or last fol-
low-up visit, and DFS as the time between surgery and the
first verified event. Differences between curves were
evaluated by the log-rank test. To identify independent
prognostic factors with significant impact on DFS and OS,
multivariate analyses were performed using the Cox pro-
portional hazards model. Calculating the exponential of the
regression coefficients from the Cox model provided an
estimate of the hazard ratio (HR) and the 95 % CI. Stability
of models was guaranteed by backward fitting procedure. A
p value of 0.05 or less was considered statistically signif-
icant. All statistical analysis was performed using SPSS
software 11.0 (SPSS Inc, Chicago, IL, USA).
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RESULTS
Patient and Tumor Characteristics at Baseline
Overall, 144 patients were identified and included in the
study. All patients were treated with third-generation AIs: 56
(38.9 %) patients received letrozole, 83 (57.6 %) exemestane,
and 5 (3.5 %) anastrozole. Patients’ characteristics are illus-
trated in Table 1. Mean age was 76.4 years (±8.2 years), with
131 (90.3 %) patients being older than 65 years. More than
half of the study population had a tumor size [3 cm in the
largest diameter, and the most frequent cancer histotype was
invasive ductal carcinoma. Tumor grade was G1 in 95 (66 %)
patients, and Ki-67 was B14 % in 88 (61.1 %) patients. Only
13 (9.0 %) patients had HER2-positive tumor. The mean
duration of NET was 5.7 months (±1.5 months).
Clinical Response and Surgery Outcome
Of 135 patients evaluable for clinical response, CR was
obtained in 13 (9.6 %), PR in 104 (77.0 %), SD in 16
(11.8 %), and PD in 2 (1.5 %). The type of hormonal agent
used did not significantly influence clinical response (data
not shown). With the exception of four patients with PR
who required mastectomy, all patients reporting objective
response (CR ? PR) received BCS. Axillary lymph node
dissection was performed in 97 (67.4 %) patients, includ-
ing nine with nodal involvement at sentinel node biopsy at
surgery.
TABLE 1 Pre-treatment clinical characteristics of patients
Variable
Mean age at surgery, years (mean ± SD) 76.4 ± 8.2
Age at surgery (years) [n (%)]
B65 14 (9.7)
[65 131 (90.3)
Clinical T (cm) [n (%)]
B3 66 (45.8)
[3 78 (54.2)









Molecular subtype [n (%)]
HER-2 negative 131 (91.0)
HER-2 positive 13 (9.0)




Duration of NET, months (mean ± SD) 5.7 ± 1.5
BCS breast conservative surgery, NET neoadjuvant endocrine therapy,
HER-2 human epidermal growth factor receptor 2
TABLE 2 Univariate and
multivariate analysis of
variables predictive of BCS
surgery
Bold values indicate significant
p values






human epidermal growth factor
receptor 2
Variable Univariate Multivariate
Odds ratio (95 % CI) p Value Odds ratio (95 % CI) p Value
Age at surgery (years)
[65 1.00 1.00
B65 2.42 (0.30–19.59) 0.407 2.92 (0.27–21.37) 0.376
Clinical T (cm)
[3 1.00 1.00
B3 2.79 (1.03–7.55) 0.044 5.48 (1.35–20.20) 0.017
Molecular subtype
HER-2 positive 1.00 1.00
HER-2 negative 5.75 (1.72–19.15) 0.004 4.93 (1.09–19.85) 0.050
Grade
G2–G3 1.00 1.00
G1 3.01 (1.17–7.80) 0.023 2.35 (0.68–8.12) 0.175
Ki-67 (%)
[14 1.00 1.00
B14 2.03 (0.77–5.39) 0.154 2.37 (0.54–10.27) 0.250
Duration of NET 1.05 (0.77–1.43) 0.753 0.99 (0.66–1.50) 0.942
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After NET, BCS was performed in 121 (84 %) patients and
mastectomy in 23 (16 %) patients. The probability of
achieving BCS according to the clinicopathologic character-
istics of patients is shown in Table 2. At univariate analyses,
factors predictive for BCS were cT B 3 cm (p = 0.031),
HER-2 negativity (p = 0.002), and grade G1 (p = 0.02). At
multivariate analyses, only a small tumor size, i.e. cT B 3 cm
at diagnosis (p = 0.017) and HER-2 negativity (p = 0.05)
remained significant predictors of BCS.
Pathological Response and Adjuvant Therapy
A pCR (ypT0/is; ypN0) was obtained in only two patients,
and absence of cancer in the breast but not in the nodes (ypT0/
is; ypN1) in three patients. After surgery, adjuvant treatment
with AIs was continued in all patients, but in 22 patients it was
preceded by adjuvant chemotherapy. A total of 125 (87 %)
patients maintained the same AI in the adjuvant setting.
Patients with non-responsive tumor were switched to another
non-cross-resistant agent: 14 (10 %) from letrozole to exe-
mestane, and 5 (3 %) from exemestane to letrozole. Of 13
patients with HER2-positive tumors, 7 received trastuzumab,
in 4 cases in combination with chemotherapy.
Adjuvant radiotherapy was delivered to 77 (64 %) of
121 patients who underwent BCS, and to 5 (22 %) of 23
patients who underwent mastectomy. Radiotherapy was not
delivered to 44 (36 %) patients with BCS and to 9 (64 %)
of 14 patients with mastectomy.
TABLE 3 Univariate analysis
of factors predictive of 5-year
disease-free survival and overall
survival
Bold values indicate significant
p values
HR hazard ratio, CI confidence
interval, HER-2 human
epidermal growth factor





Variable n Disease-free survival Overall survival
5-year
(%)a
HR (95 % CI) p Value 5-year
(%)a
HR (95 % CI) p Value
Age at surgery (years)
B65 14 83.1 1.00 92.3 1.00
[65 131 83.5 1.02 (0.24–4.37) 0.981 81.7 1.12 (0.26–4.82) 0.882
Molecular subtype
HER-2 negative 131 86.4 1.00 83.7 1.00
HER-2 positive 13 47.5 3.93 (1.44–10.75) 0.008 70.3 1.92 (0.65–5.64) 0.235
Grade (basal)
G1 95 94.3 1.00 91.8 1.00
G2–G3 42 57.3 8.57 (3.14–23.42) \0.001 62.6 4.35 (1.84–10.27) 0.001
Type of surgery
BCS 121 88.6 1.00 86.1 1.00
Mastectomy 23 57.5 4.46 (1.88–10.59) 0.001 65.8 4.15 (1.85–9.29) 0.001
Ki67 (basal; %)
B14 88 88.9 1.00 81.7 1.00
[14 40 64.6 4.09 (1.67–10.04) 0.002 76.1 1.53 (0.66–3.55) 0.317
T stage (after surgery)
yT0–yT1 66 94.5 1.00 85.6 1.00
yT2–yT3 78 74.5 5.42 (1.60–18.41) 0.007 79.7 2.36 (0.94–5.95) 0.069
No. of metastatic nodes
None 85 91.1 1.00 83.6 1.00
B3 34 86.7 1.34 (0.39–4.58) 0.640 88.1 1.48 (0.13–1.81) 0.259
[3 25 55.9 5.56 (2.12–11.62) 0.001 68.8 2.22 (0.93–5.31) 0.073
Adjuvant RT
No 62 86.7 1.00 80.6 1.00
Yes 82 80.9 0.64 (0.26–1.60) 0.344 85.2 1.38 (0.62–3.09) 0.425
Adjuvant chemotherapy
No 122 88.3 1.00 84.1 1.00
Yes 22 61.5 3.36 (1.39–8.11) 0.007 75.3 1.62 (0.64–4.09) 0.305
Stage (after surgery)
0–I 48 97.9 1.00 87.5 1.00
II 66 83.2 7.18 (0.91–56.09) 0.060 86.3 1.18 (0.40–3.48) 0.759
III 27 59.2 20.29 (2.60–58.52) 0.004 71.1 2.68 (0.89–8.06) 0.080
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Long-Term Outcome
After a median follow-up of 49 months (range 3–
119 months), 4 (3 %) patients had a local relapse, 18
(12.5 %) had distant metastases, and 24 (17 %) died. Results
of univariate analysis of factors associated with DFS and OS
are shown in Table 3. In particular, HER-2-negative tumor
(p = 0.08), grade G1 (p \ 0.001), achievement of BCS
(p = 0.001), Ki-67 B 14 % (p = 0.002), residual tumor
B2 cm (p = 0.007), number of metastatic nodes B3
(p = 0.001), administration of adjuvant chemotherapy
(p = 0.007), and stage I disease after surgery (p = 0.004)
were associated with a better DFS. Only BCS and grade G1
(p = 0.001) were predictors of a better OS. Figure 1 refers to
Kaplan–Meier analysis of DFS (Fig. 1a) and OS (Fig. 1b)
according to type of surgery. At 5 years of follow-up, the
estimated cumulative DFS rate was 88.6 % for BCS and
57.5 % for mastectomy, while the estimated cumulative OS
rate was 86.1 % for BCS and 65.8 % for mastectomy.
At multivariate analyses, achievement of BCS (p = 0.009),
tumor grade G1 (p = 0.01), and a residual tumor size B2 cm
after surgery (p = 0.005) resulted as independent prognostic
factors for DFS, while BCS and grade G1 maintained their
significativity for OS (p = 0.002 and p = 0.005, respectively)
[Table 4].
DISCUSSION
This retrospective study was carried out in postmeno-
pausal breast cancer patients who were candidates for
mastectomy with the aim of evaluating the efficacy of NET
with AIs in terms of clinical outcome and obtainment of
breast conservation.
All women evaluated in the present study received NET
with a third-generation AI—letrozole, anastrozole, or ex-
emestane. The three agents are considered equivalent in
their antitumor activity and are supposed to have similar
efficacy in both the neoadjuvant and adjuvant setting.23
BCS was performed in 121 (84 %) of 144 patients. This
BCS rate is greater than that reported in clinical studies in
which AIs had been administered as the primary treatment
in patients with breast cancer.16,17,19 In particular, the P024
study17 comparing letrozole versus tamoxifen, the
IMPACT19 and the PROACT16 trials, both comparing an-
astrozole versus tamoxifen, reported BCS rates of 45, 46,
and 43 %, respectively, in the arm receiving AIs. The short
duration of NET (only 3 months in the IMPACT and
PROACT trials, and 4 months in the P024 study) is likely
responsible for the low response rate observed in these
studies. In another phase II study, the American College of
Surgeons Oncology Group (ACOSOG) Z1031 trial, com-
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FIG. 1 Cumulative disease-free survival a and overall survival b
stratified by type of surgery. BCS breast conservative surgery
TABLE 4 Multivariate analysis of factors predictive of 5-year dis-
ease-free survival and overall survival
HR (95 % CI) p Value
Disease-free survival
Grade (G2–G3 vs. G1) 4.56 (1.44–12.42) 0.010
Type of surgery (mastectomy
vs. BCS)
8.11 (1.68–19.08) 0.009
T stage (yT2–yT3 vs. yT0–yT1) 7.92 (1.88–13.43) 0.005
Overall survival
Grade (G2–G3 vs. G1) 4.26 (1.57–11.61) 0.005
Type of surgery (mastectomy
vs. BCS)
8.86 (2.29–7.47) 0.002
Bold values indicate significant p values
BCS breast conservative surgery
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the endocrine agents were administered for about 4 months
and the overall BCS rate was 83.1 % in the women con-
sidered ‘marginal for BCS’ at baseline, and around 50 % in
the women categorized as ‘only eligible for mastectomy’.23
It is now generally accepted that the minimum duration of
NET should be at least 4 months, but better results might
be obtained with longer extension of time.24,25 A recent
study comparing 4, 8, and 12 months of neoadjuvant le-
trozole showed that there was a time-dependent increase in
overall response rate, which reflected in BCS rate ranging
from 80 to 87.5 %.26 In our cohort, the duration of NET did
not significantly influence the type of surgery, but the
median time of AI administration was 6 months, with 85 %
of patients receiving NET for more than 5 months. More-
over, our series encompassed highly endocrine-responsive
tumors (ER expression C60 %). This may contribute to the
high rate of BCS we observed, since the probability of
achieving a better response has been related to the level of
expression of hormonal receptors.27 A trial on exemestane
as NET set a cutoff C50 % of ER-positive cells for patient
eligibility.28 The above cited Z1031 trial23 required ER-
positive disease with high ER expression, i.e. Allred score
of 6 to 8.29 It has been suggested that tumors with both ER
and PR positivity in more than 50 % of the cells might be
considered highly endocrine responsive, while a positivity
in less than 50 % of the cells predicts an incomplete
endocrine responsiveness.3 In our study, all patients had
tumors with ER expression C60 %, and more than half
(63 %) had both ER and PR C 50 %.
The variables statistically associated with the achieve-
ment of BCS were tumor size\3 cm at diagnosis and HER-2
negativity. The latter result probably reflects the intrinsic
hormonal resistance of HER-2-positive tumors.30,31
BCS was performed in patients reporting clinical
objective response (CR ? PR) and was significantly asso-
ciated with longer DFS and OS. Given that achievement of
BCS strongly correlates with the clinical response of the
primary tumor, the latter was not included as a variable in
the multivariate analyses. We observed only two pCRs
(1.4 %), in accordance with the low rate reported in NET
studies, ranging from 1 to 10 %.19,32–34 pCR, which is the
most important prognostic factor for neoadjuvant chemo-
therapy, is not an appropriate surrogate marker for
prognosis in patients with HR-positive tumors. In fact,
patients with this subtype of breast cancer rarely obtain a
pCR but have a good outcome, even in presence of residual
disease.3–8
Interestingly, our data indicate that grade G1 is a tumor
biological characteristic strongly associated with longer
DFS and OS. It has long been established that patients with
well-differentiated breast cancer, including those with HR-
positive tumor, have a better survival than those with G2
and G3 tumors.35 However, in the last St. Gallen
Consensus Conference,24,36 the Ki-67 proliferation mar-
ker,37 rather than grading, was taken into consideration for
the separation of HR-positive/HER-2-negative tumors in
luminal A and luminal B subtypes, two groups with dif-
ferent prognosis.38 This recommendation was based on
data suggesting that Ki-67 levels [14 % were able to
identify a high-risk group in terms of prognosis.39,40 In the
absence of Ki-67 determination, grading is still used to
differentiate luminal molecular subtypes.8 The prognostic
role of Ki-67 in breast cancer is controversial. Two dif-
ferent meta-analyses of studies on early breast cancer 41,42
and a recent large retrospective study 43 have shown that
high levels of Ki-67 are associated with a worse prognosis.
In addition, in HR-positive breast cancer, reduction of Ki-
67 after 2 weeks of NET correlated with better response
and recurrence-free survival.44 On the contrary, another
study conducted on patients with breast cancer receiving
neoadjuvant chemotherapy showed no predictive or prog-
nostic value of Ki-67 in HR-positive/HER2-negative
tumors.45 Given the great heterogeneity of patients in the
different studies, and the different methods utilized to
determine and score Ki-67, the American Society of
Clinical Oncology (ASCO) Tumor Marker Guidelines
Committee did not advise the routine use of Ki-67 for the
estimation of prognosis in patients with breast cancer.46 In
our study, neither baseline expression of Ki-67 nor Ki-67
variations after NET influenced the long-term outcome
(data not shown). It has been reported that the prognostic
value of Ki-67 is mainly attributed to the histological grade
G 2,47,48 and the prevalence of patients with G1 tumors
(67 %) in our cohort may justify the lack of prognostic
value of Ki-67. Another study evaluated the long-term
outcome of patients after NET, showing that a low-risk
profile (i.e. pT0/1, pN0, Ki6-67 \2.7 % and Allred score
3–8 for ER status, the so-called PEPI score) allowed to
identify a group of patients with a very low risk of disease
progression.49 Our data are in agreement with these results
only for pathological stage, but not for Ki-67 and ER sta-
tus, likely for the very high ER positivity and G1 tumor
percentage in our patients’ population, as emphasized
above.
Finally, the high rate of BCS in our study is especially
relevant considering that more than 90 % of the patients
were older than 65 years. In fact, in elderly patients most
authors recommend a conservative surgery based on the
increased risk of death from concomitant disease and the
reduced risk of local recurrence.33,50,51 Moreover, the
preservation of body image in older patients is an important
psychological factor influencing both the quality of life and
mental health.52–54
The limits of this retrospective study are mainly repre-
sented by single surgery team evaluation for patient
eligibility to BCS prior to neoadjuvant therapy and the
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relatively small number of events to investigate long-term
outcomes.
CONCLUSIONS
We show that elderly breast cancer patients with a tumor
size \3 cm at diagnosis and HER-2-negativity have a
higher probability of achieving BCS after NET. Moreover,
patients treated with BCS and with grade G1 tumor have a
reduced risk of recurrence and death in the long-term fol-
low-up. It is likely these patients are those who will benefit
the most from preoperative endocrine therapy.
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